Personalized risk tools for medication side effects in adults with heart disease
Development of Integrated Precision Medicine Models in Adults with Cardiovascular Disease
['FUNDING_R03'] · UNIVERSITY OF FLORIDA · NIH-11136243
Using health and genetic information from a large national dataset, this project will build tools to help spot adults with heart disease who might get side effects from statins or common blood thinners like clopidogrel.
Quick facts
| Phase | ['FUNDING_R03'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF FLORIDA (nih funded) |
| Locations | 1 site (GAINESVILLE, UNITED STATES) |
| Trial ID | NIH-11136243 on ClinicalTrials.gov |
What this research studies
This project uses existing health records and genetic data from the All of Us Research Program to create predictive models for medication side effects and poor outcomes in people with heart disease. The team will focus on side effects from statins (including muscle symptoms) and problems after taking P2Y12 blood thinners such as clopidogrel. Researchers will combine clinical information, medication records, and genetic markers to make models that reflect diverse, real-world populations rather than mostly European or Asian groups. The goal is to produce tools that could inform safer medicine choices for a broad range of adults with cardiovascular disease.
Who could benefit from this research
Good fit: Adults (age 21+) with cardiovascular disease who take or may take statins or P2Y12 inhibitors such as clopidogrel, especially those from underrepresented racial and ethnic groups, are the primary population this work is meant to help.
Not a fit: People who are not taking statins or P2Y12 inhibitors, children under 21, or individuals without available clinical or genetic data in the All of Us dataset are unlikely to benefit directly from this specific project.
Why it matters
Potential benefit: If successful, these tools could help doctors choose safer medications and reduce preventable side effects and bad outcomes for people with heart disease.
How similar studies have performed: Prior pharmacogenetic studies have shown promise for predicting clopidogrel response and some statin harms, but most were done in European or Asian cohorts and lacked broad, real-world validation in diverse populations.
Where this research is happening
GAINESVILLE, UNITED STATES
- UNIVERSITY OF FLORIDA — GAINESVILLE, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: MCDONOUGH, CAITRIN W — UNIVERSITY OF FLORIDA
- Study coordinator: MCDONOUGH, CAITRIN W
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.